Electra Therapeutics, Inc. (NASDAQ:ETRA) Stock Has Average Target Price of $34.00 According to Brokerages

Key Points

• Analysts are broadly bullish on Electra Therapeutics, with a consensus “Buy” rating from five analysts and an average 12-month price target of $34.00.
• Recent coverage included price targets of $36 from Evercore and $32 from Jefferies, while Cantor Fitzgerald and TD Cowen also initiated favorable ratings.
• The stock opened at $8.75, down 2.1%, near its 52-week low of $8.50. Separately, two directors each purchased 1.33 million shares at $15 per share, increasing their positions by 35.15%.

Shares of Electra Therapeutics, Inc. (NASDAQ:ETRA - Get Free Report) have earned a consensus recommendation of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.00.

A number of analysts have recently weighed in on ETRA shares. Cantor Fitzgerald assumed coverage on Electra Therapeutics in a research note on Tuesday. They issued an "overweight" rating for the company. Evercore started coverage on shares of Electra Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $36.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research report on Tuesday. They set a "buy" rating and a $32.00 target price on the stock. Zacks Research upgraded shares of Electra Therapeutics to a "hold" rating in a research report on Wednesday. Finally, TD Cowen started coverage on shares of Electra Therapeutics in a research note on Tuesday. They set a "buy" rating on the stock.

Electra Therapeutics Trading Down 2.1%

Shares of NASDAQ:ETRA opened at $8.75 on Friday. Electra Therapeutics has a 52 week low of $8.50 and a 52 week high of $15.50.

Insider Activity at Electra Therapeutics

In related news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the business's stock in a transaction dated Monday, September 21st. The shares were bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the purchase, the director directly owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Carl Gordon bought 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The shares were bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares of the company's stock, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Electra Therapeutics

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.